| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 05/02/2001 | EP1095652A2 Melanins with improved ability to inhibit HIV replication |
| 05/02/2001 | EP1095651A2 Multipor food protection |
| 05/02/2001 | EP1095061A1 Peptides based on the sequence of human lactoferrin and their use |
| 05/02/2001 | EP1095059A1 Chemotaxis inhibiting protein of staphylococcus (chips) and its use |
| 05/02/2001 | EP1095058A1 Glycopeptide antibiotics, combinatorial libraries of glycopeptide antibiotics and methods of producing same |
| 05/02/2001 | EP1095050A1 Phosphorous organic compounds and their use |
| 05/02/2001 | EP1095031A1 Antiviral macrocyclic compounds |
| 05/02/2001 | EP1095029A1 Piperazine derivatives inhibiting human immunodeficiency virus replication |
| 05/02/2001 | EP1095020A1 2-aminopyridine erivatives, their use as medicines and pharmaceutical compositions containing them |
| 05/02/2001 | EP1095007A1 Water-soluble zinc pyruvates or their hydrates, method for the production thereof and their use |
| 05/02/2001 | EP1095003A1 Cytokine production and tyrosine kinase inhibitors |
| 05/02/2001 | EP1094837A2 Porcine circovirus and parvovirus vaccine |
| 05/02/2001 | EP1094833A2 Oxidized thymosin beta 4 |
| 05/02/2001 | EP1094822A1 Water miscible macrolide solutions |
| 05/02/2001 | EP1094814A2 Methods and compositions for increasing penetration of hiv protease inhibitors |
| 05/02/2001 | EP1094810A1 Use of prenyltransferase inhibitors for preparing a medicine for treating pathologies resulting from heterotrimeric g protein membrane fixation |
| 05/02/2001 | EP1094807A1 Vitamin e and esters thereof for use in the topical treatment of mucosal pathologies |
| 05/02/2001 | EP1094800A2 PEPTIDYL-PROLYL $i(CIS)-TRANS ISOMERASE INHIBITORS AND USES THEREFOR |
| 05/02/2001 | EP1094711A1 Methods for eradication of nanobacteria |
| 05/02/2001 | EP0988304B1 Nucleosides analogues, such as antivirals including inhibitors of retroviral reverse transcriptase and the dna polymerase of hepatitis b virus (hbv) |
| 05/02/2001 | EP0817860B1 Pseudotyped retroviral particles |
| 05/02/2001 | CN1293668A Process for synthesis of HTV protease inhibitors |
| 05/02/2001 | CN1293568A Lipophilic microparticles containing protein drug or antigen and formulation comprising same |
| 05/02/2001 | CN1293045A Mixture of Chinese and Western medicine for treating vulvopathy and venereal disease |
| 05/02/2001 | CN1293042A Propolis honey and its preparing process |
| 05/02/2001 | CN1065238C Intermediate compound suitable for synthesing modified oligodeoxynucleotide acid |
| 05/02/2001 | CN1065237C Cyclopentane-and-cyclo pentene-beta-amino acids |
| 05/02/2001 | CN1065139C Agent for promoting of phafocyte |
| 05/01/2001 | US6225494 Trisubstituted phenyl derivatives having retinoid agonist or inverse agonist type biological activity |
| 05/01/2001 | US6225481 Robustaflavone, intermediates and analogues and method for preparation thereof |
| 05/01/2001 | US6225458 Process for the production of DNA comprising the genome of the hepatitis B virus and vector including it |
| 05/01/2001 | US6225457 Polynucleotide sequences associated with bacterial proteins; for detection of bactericides |
| 05/01/2001 | US6225455 Constructs for producing phosphorylated fusion proteins |
| 05/01/2001 | US6225345 Azahexane derivatives as substrate isosters of retroviral asparate proteases |
| 05/01/2001 | US6225341 For inhibiting neuraminidase; for therapy and prophylaxis of virus infection |
| 05/01/2001 | US6225328 Adamantyl-substituted retinoids and pharmaceutical/cosmetic compositions comprised thereof |
| 05/01/2001 | US6225323 Activated iododerivatives for the treatment of cancer and AIDS |
| 05/01/2001 | US6225317 Reverse transcriptase inhibitor |
| 05/01/2001 | US6225307 Caprolactam-phenyl phenylcarbamate |
| 05/01/2001 | US6225300 TNF receptor and steroid hormone in a combined therapy |
| 05/01/2001 | US6225290 Provides advantages:short term or long term cures and/or treatment, avoids invasive procedures, oral administration, naked dna is used rather than viral vectors, side-effects of long term gene administration can be avoided |
| 05/01/2001 | US6225289 Methods and compositions for preserving adenoviral vectors |
| 05/01/2001 | US6225288 Implicated in modulating apoptosis; treatment of:cardiac and cerebral ischemia/reperfusion injury, spinal cord injury and organ damage during transplantation, chronic neurodegenerative diseases, immunodeficiency, diabetes, alopecia, aging |
| 05/01/2001 | US6225113 Genetically engineered vector for the transcription of heterologous genes in cells |
| 05/01/2001 | US6225102 Amino acid sequence of guanosine triphosphatase from streptococcus; diagnosis; prophylaxis; drug screening; bactericides; bacteriostats |
| 05/01/2001 | US6225098 UDP-N-acetylenolpyruvyglucosamine reductase |
| 05/01/2001 | US6225091 Multimeric hybrid gene encoding a chimeric protein which confers protection against parainfluenza virus and respiratory synctial virus |
| 05/01/2001 | US6225087 Polynucleotide which codes for a polypeptide of defined amino acid sequence; drug screening of bactericides against streptococcus; otitis media; conjunctivitis; pneumonia; meningitis; sinusitis; pleural empyema; endocarditis |
| 05/01/2001 | US6225083 Nucleotide and amino acid sequences of membrane protein involved in cell division; drug screening; bactericides; bacteriostats; antibiotics; for meningitis, sinusitis, conjunctivitis, otitis media, and endocarditis |
| 05/01/2001 | US6224910 Method for the preparation of an enteric coated high drug load pharmaceutical composition |
| 05/01/2001 | US6224891 Compounds and methods for the treatment of bacterial dysentery using antibiotics and toxin binding oligosaccharide compositions |
| 05/01/2001 | US6224887 Antifungal nail lacquer and method using same |
| 05/01/2001 | US6224881 DNA molecule fragments encoding for cellular uptake of Mycobacterium tuberculosis and uses thereof |
| 05/01/2001 | US6224880 Vaccines |
| 05/01/2001 | US6224879 Genetic engineering |
| 05/01/2001 | US6224878 Culture product; genetic engineering |
| 05/01/2001 | US6224869 Isolated polypeptide |
| 05/01/2001 | CA2268703C Enantiomerically pure .beta.-d-dioxolane nucleosides with selective anti-hepatitis b virus activity |
| 05/01/2001 | CA2139169C Antiherpes peptidomimetic compounds |
| 05/01/2001 | CA2067333C Production of genetically-engineered vaccines for aids and retroviral diseases |
| 04/26/2001 | WO2001029233A2 Chimeric immunogenic compositions and nucleic acids encoding them |
| 04/26/2001 | WO2001029219A1 Human cub-domain-containing protein and gene encoding the same |
| 04/26/2001 | WO2001029206A1 Methods of producing differentiated progenitor cells and lineage-defective embryonic stem cells |
| 04/26/2001 | WO2001029201A1 Expression of recombinant mature lysostaphin |
| 04/26/2001 | WO2001029198A1 Polypeptide fragments comprising c-terminal portion of helicobacter catalase |
| 04/26/2001 | WO2001029193A2 Cell constructs that are suitable for immunotherapy, the production and the use thereof |
| 04/26/2001 | WO2001029182A1 Novel compound, wf217 |
| 04/26/2001 | WO2001029178A2 Epo primary response gene 1, eprg1 |
| 04/26/2001 | WO2001029084A2 Novel human proteins and polynucleotides encoding the same |
| 04/26/2001 | WO2001029073A1 Methods for improving secondary metabolite production in fungi |
| 04/26/2001 | WO2001029070A2 Modulation of t cell differentiation for the treatment of t helper cell mediated diseases |
| 04/26/2001 | WO2001029061A1 Novel fusidic acid derivatives |
| 04/26/2001 | WO2001029054A2 Medicaments for treatment of respiratory syncytial virus infections |
| 04/26/2001 | WO2001029050A2 Condensed pyrrole derivatives as neuraminidase inhibitors |
| 04/26/2001 | WO2001029049A2 Imidazole derivatives as phosphodiesterase vii inhibitors |
| 04/26/2001 | WO2001029043A1 Ucs1025 derivatives |
| 04/26/2001 | WO2001029042A1 Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase |
| 04/26/2001 | WO2001029037A2 Condensed naphthyridines as hiv reverse transcriptase inhibitors |
| 04/26/2001 | WO2001029035A1 4-oxoquinolizine antimicrobials having 2-pyridone skeletons as the partial structure |
| 04/26/2001 | WO2001029028A1 9- (piperazinylalkyl) carbazoles as bax-modulators |
| 04/26/2001 | WO2001029026A1 Phenyl- and pyridyl-tetrahydro-pyridines having tnf inhibiting activity |
| 04/26/2001 | WO2001029021A1 Neuraminidase inhibitors |
| 04/26/2001 | WO2001029020A2 Neuraminidase inhibitors |
| 04/26/2001 | WO2001029013A1 Process for preparing oxazolines from tetrahydrofurans |
| 04/26/2001 | WO2001029007A1 Pyrazole derivatives as cannabinoid receptor antagonists |
| 04/26/2001 | WO2001028996A2 Pyrrolidine derivatives, their preparation and their use as inhibitors of neuraminidases |
| 04/26/2001 | WO2001028600A1 Conveyance of anti-infective activity to wound dressings |
| 04/26/2001 | WO2001028585A1 Novel process for making human papillomavirus virus-like particles with improved properties |
| 04/26/2001 | WO2001028575A1 Proteoglycan, a bioactive substance from plants |
| 04/26/2001 | WO2001028572A1 Iodine containing antimicrobial compositions for mastitis control |
| 04/26/2001 | WO2001028557A1 Cannabimimetic indole derivatives |
| 04/26/2001 | WO2001028556A2 Compositions for prevention and treatment of cold and influenza-like symptoms and their methods of use |
| 04/26/2001 | WO2001028552A2 Antimicrobial compositions comprising pyroglutamic acid and optionally metal salts |
| 04/26/2001 | WO2001028537A2 Bissulfonamide derivatives as enzyme inhibitors |
| 04/26/2001 | WO2001028523A1 Powder pharmaceutical formulations |
| 04/26/2001 | WO2001028498A2 Retro-anandamides, high affinity and stability cannabinoid receptor ligands |
| 04/26/2001 | WO2001028497A2 Novel bicyclic cannabinoid agonists for the cannabinoid receptor |
| 04/26/2001 | WO2001028492A2 Polyanhydrides with biologically active degradation products |
| 04/26/2001 | WO2001028338A2 Antimicrobial compositions comprising a benzoic acid analog and a metal salt |
| 04/26/2001 | WO2001005934A3 Feline calicivirus genes and vaccines, in particular recombined vaccines |